SG148034A1 - Non-neurotoxic plasminogen activating factors for treating stroke - Google Patents

Non-neurotoxic plasminogen activating factors for treating stroke

Info

Publication number: SG148034A1
Authority: SG; Singapore
Prior art keywords: activating factors; plasminogen activating; neurotoxic plasminogen; treating stroke; stroke
Prior art date: 2001-11-02

Application number

SG200604427-5A

Other languages

English (en)

Inventor

Mariola Soehngen

Wolfgang Soehngen

Wolf-Dieter Schleuning

Robert Medcalf

Original Assignee

Paion Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-02

Filing date

2002-10-31

Publication date

2008-12-31

2002-10-31 Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh

2008-12-31 Publication of SG148034A1 publication Critical patent/SG148034A1/en

Links

102000013566 Plasminogen Human genes 0.000 title abstract 3
108010051456 Plasminogen Proteins 0.000 title abstract 3
230000003213 activating effect Effects 0.000 title abstract 3
231100000501 nonneurotoxic Toxicity 0.000 title abstract 3
208000006011 Stroke Diseases 0.000 abstract 3
230000001225 therapeutic effect Effects 0.000 abstract 2
241000288900 Desmodus rotundus Species 0.000 abstract 1
ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)

SG200604427-5A 2001-11-02 2002-10-31 Non-neurotoxic plasminogen activating factors for treating stroke SG148034A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10153601A DE10153601A1 (de)	2001-11-02	2001-11-02	DSPA zur Behandlung von Schlaganfall
EP01130006A EP1308166B1 (fr)	2001-11-02	2001-12-17	Facteurs non neurotoxiques activateurs du plasminogène pour le traitement de l'accident vasculaire cérébral

Publications (1)

Publication Number	Publication Date
SG148034A1 true SG148034A1 (en)	2008-12-31

Family

ID=7704253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200604427-5A SG148034A1 (en)	2001-11-02	2002-10-31	Non-neurotoxic plasminogen activating factors for treating stroke

Country Status (26)

Country	Link
US (7)	US20050048027A1 (fr)
EP (4)	EP1308166B1 (fr)
JP (2)	JP5004407B2 (fr)
KR (3)	KR20090128583A (fr)
CN (2)	CN100446810C (fr)
AT (3)	ATE440614T1 (fr)
AU (1)	AU2002350660C1 (fr)
BR (1)	BR0213856A (fr)
CA (1)	CA2465792C (fr)
CY (3)	CY1108446T1 (fr)
DE (3)	DE10153601A1 (fr)
DK (3)	DK1308166T3 (fr)
EA (3)	EA013707B1 (fr)
ES (3)	ES2332576T3 (fr)
HR (1)	HRP20040383B1 (fr)
HU (1)	HU230163B1 (fr)
IL (1)	IL205695A0 (fr)
MX (1)	MXPA04004155A (fr)
NO (1)	NO329789B1 (fr)
NZ (2)	NZ532903A (fr)
PL (1)	PL208343B1 (fr)
PT (3)	PT1308166E (fr)
SG (1)	SG148034A1 (fr)
SI (2)	SI1997510T1 (fr)
WO (1)	WO2003037363A2 (fr)
ZA (1)	ZA200403285B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10153601A1 (de) *	2001-11-02	2003-05-22	Paion Gmbh	DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) *	2003-05-02	2008-03-06	Paion Deutschland Gmbh	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
CA2524573A1 (fr) *	2003-05-02	2004-11-11	Paion Deutschland Gmbh	Injection intraveineuse d'activateurs de plasminogene non neurotoxiques pour le traitement de l'attaque cerebrale
AU2003227721A1 (en) *	2003-05-02	2004-11-23	Paion Gmbh	Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20060135425A1 (en) *	2003-05-02	2006-06-22	Paion Deutschland Gmbh	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080213244A1 (en) *	2003-05-05	2008-09-04	Wolfgang Sohngen	Glutamate Receptor Antagonists as Neuroprotectives
DE10342518A1 (de) *	2003-09-12	2005-05-12	Paion Gmbh	Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
JP2006241109A (ja) *	2005-03-04	2006-09-14	Paion Deutschland Gmbh	ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
AR068914A1 (es) *	2007-10-18	2009-12-16	Paion Deutschland Gmbh	Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
WO2011107299A2 (fr)	2010-04-16	2011-09-09	Paion Deutschland Gmbh	Procédé de préparation de dspa alpha1 recombiné
JP6085568B2 (ja) *	2011-01-05	2017-02-22	スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓＮＶ	プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en)	2011-08-12	2017-05-09	Thrombogenics Nv	Plasminogen and plasmin variants
CA3176021A1 (fr) *	2018-12-28	2020-07-02	Catalyst Biosciences, Inc.	Polypeptides activateurs de plasminogene de type urokinase modifies et leurs procedes d'utilisation
US11613744B2 (en)	2018-12-28	2023-03-28	Vertex Pharmaceuticals Incorporated	Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL68561A (en)	1982-05-05	1991-01-31	Genentech Inc	Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US5244806A (en) *	1985-08-26	1993-09-14	Eli Lilly And Company	DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
DE3643158A1 (de)	1986-04-21	1987-11-19	Boehringer Mannheim Gmbh	Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH087179B2 (ja) *	1986-09-27	1996-01-29	日本碍子株式会社	ガスセンサ
WO1988005081A2 (fr) *	1986-12-30	1988-07-14	Cetus Corporation	Nouveaux activateurs du plasminogene
IL87276A (en) *	1987-08-03	1995-07-31	Fujisawa Pharmaceutical Co	Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
EP0386240B1 (fr) *	1987-10-29	1995-07-19	Yamanouchi Pharmaceutical Co. Ltd.	Nouveaux composes polypeptidiques
US5094953A (en) *	1988-03-21	1992-03-10	Genentech, Inc.	Human tissue plasminogen activator variants
DK176140B1 (da)	1988-07-20	2006-09-25	Schering Ag Patentabteilung	Flagermusspyt-plasminogenaktivatorer
DE3825253A1 (de)	1988-07-25	1990-02-01	Boehringer Mannheim Gmbh	T-pa-derivat und seine herstellung
US5714145A (en) *	1988-09-02	1998-02-03	Genentech, Inc.	Tissue plasminogen activator having zymogenic or fibrin specific properties
JPH0273774A (ja) *	1988-09-09	1990-03-13	Nec Corp	ファクシミリ装置
GB8901422D0 (en) *	1989-01-23	1989-03-15	Fujisawa Pharmaceutical Co	New tissue plasminogen activator
DE3903581A1 (de) *	1989-02-07	1990-08-16	Boehringer Mannheim Gmbh	Gewebs-plasminogenaktivator-derivat
US5676947A (en) *	1989-02-07	1997-10-14	Boehringer Manneheim Gmbh	Method for treating thromboembolic conditions using thrombolytically active proteins
US6008019A (en)	1989-02-13	1999-12-28	Schering Aktiengesellschaft	Plasminogen activator from saliva of the vampire bat
CA2046632C (fr) *	1989-02-13	1999-05-11	Schering Aktiengesellschaft	Agent throbolytique provenant de la salive de chauve-souris vampire
DE3917949A1 (de) *	1989-05-30	1991-01-24	Schering Ag	Neues thrombolytikum
DE3904580A1 (de)	1989-02-13	1990-08-16	Schering Ag	Neues thrombolytikum
JPH04506148A (ja) *	1989-04-07	1992-10-29	カンサーフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング）	ウロキナーゼ型プラスミノーゲン活性化因子レセプター
US5891664A (en) *	1989-04-07	1999-04-06	Cancerforskningsfondet Af 1989	Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
JPH0352119A (ja) *	1989-07-19	1991-03-06	Matsushita Electric Ind Co Ltd	光学式記録再生装置
NL8902454A (nl)	1989-10-03	1991-05-01	Stichting Centraal Lab	Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5326700A (en) *	1990-11-06	1994-07-05	Eli Lilly And Company	DNA sequences encoding t-PA derivatives with cleavable sites
DE59204945D1 (de)	1991-04-16	1996-02-15	Boehringer Mannheim Gmbh	Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
DE4123845A1 (de) *	1991-07-18	1993-01-21	Boehringer Mannheim Gmbh	Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5595736A (en) *	1991-04-22	1997-01-21	Eli Lilly And Company	Compounds and methods for treatment of thromboembolic disorders
NL9101520A (nl) *	1991-09-09	1993-04-01	Stork Fibron Bv	Werkwijze voor het vervaardigen van een eetbaar produkt.
ATE145669T1 (de)	1991-12-16	1996-12-15	Genentech Inc	T-pa substitutionsvarianten mit verbesserter fibrinspezifität
ES2107790T3 (es) *	1992-12-04	1997-12-01	Schering Ag	Inhibidor de trombina procedente de la saliva de protostomias.
US5510330A (en) *	1994-03-25	1996-04-23	Boehringer Mannheim Gmbh	Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) *	1994-06-17	1994-08-10	British Bio Technology	Thrombolytic composition
DE4423574A1 (de)	1994-07-05	1996-01-11	Boehringer Mannheim Gmbh	Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5827832A (en) *	1995-03-06	1998-10-27	Interneuron Pharmaceuticals, Inc.	Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) *	1995-09-21	1998-07-28	The Research Foundation Of State University Of New York	Method for reducing neuronal degeneration associated with seizure
US5945432A (en) *	1995-12-22	1999-08-31	The University Of Vermont And State Agricultural College	Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) *	1996-01-23	2002-06-27	Genentech, Inc.	Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en)	1996-02-05	1998-03-24	Schering Aktiengesellschaft	Method for the production of rDSPA α1
US6235947B1 (en) *	1997-04-14	2001-05-22	Takeda Chemical Industries, Ltd.	D-mannitol and its preparation
US5830349A (en) *	1996-07-22	1998-11-03	Dana Corporation	Flow inverter for filters
BR9711840A (pt) *	1996-10-01	1999-08-24	Univ Georgia Res Found	Agentes de controle de insetos biolÄgico expressando os genes para toxinas de caro especificas para insetos m-todos e composi-{es
US6008109A (en) *	1997-12-19	1999-12-28	Advanced Micro Devices, Inc.	Trench isolation structure having a low K dielectric encapsulated by oxide
KR20010069066A (ko)	2000-01-12	2001-07-23	이종원	저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
DE10008646A1 (de)	2000-02-24	2001-09-13	Kempten Elektroschmelz Gmbh	Beschichteter Formkörper aus Siliciumnitrid
GB0025473D0 (en) *	2000-10-17	2000-11-29	Pfizer Ltd	Pharmaceutical combinations
US20020089179A1 (en) *	2000-12-30	2002-07-11	Levon Guyumjan	Hose coupling apparatus and method
DE10153601A1 (de)	2001-11-02	2003-05-22	Paion Gmbh	DSPA zur Behandlung von Schlaganfall
US20060135425A1 (en) *	2003-05-02	2006-06-22	Paion Deutschland Gmbh	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080057050A1 (en) *	2003-05-02	2008-03-06	Paion Deutschland Gmbh	Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AU2003227721A1 (en)	2003-05-02	2004-11-23	Paion Gmbh	Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
CA2524573A1 (fr)	2003-05-02	2004-11-11	Paion Deutschland Gmbh	Injection intraveineuse d'activateurs de plasminogene non neurotoxiques pour le traitement de l'attaque cerebrale
US20080213244A1 (en) *	2003-05-05	2008-09-04	Wolfgang Sohngen	Glutamate Receptor Antagonists as Neuroprotectives
US20050085478A1 (en)	2003-08-22	2005-04-21	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
DE10342518A1 (de)	2003-09-12	2005-05-12	Paion Gmbh	Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es)	2007-10-18	2009-12-16	Paion Deutschland Gmbh	Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia

2001
- 2001-11-02 DE DE10153601A patent/DE10153601A1/de not_active Ceased
- 2001-12-17 EP EP01130006A patent/EP1308166B1/fr not_active Expired - Lifetime
- 2001-12-17 DK DK01130006T patent/DK1308166T3/da active
- 2001-12-17 DE DE50115077T patent/DE50115077D1/de not_active Expired - Lifetime
- 2001-12-17 PT PT01130006T patent/PT1308166E/pt unknown
- 2001-12-17 AT AT01130006T patent/ATE440614T1/de active
- 2001-12-17 ES ES01130006T patent/ES2332576T3/es not_active Expired - Lifetime
2002
- 2002-10-31 BR BR0213856-5A patent/BR0213856A/pt not_active Application Discontinuation
- 2002-10-31 AT AT02785348T patent/ATE401910T1/de active
- 2002-10-31 NZ NZ532903A patent/NZ532903A/en not_active IP Right Cessation
- 2002-10-31 DK DK02785348T patent/DK1441757T3/da active
- 2002-10-31 PL PL369872A patent/PL208343B1/pl unknown
- 2002-10-31 HU HU0402165A patent/HU230163B1/hu not_active IP Right Cessation
- 2002-10-31 CN CNB028234782A patent/CN100446810C/zh not_active Expired - Fee Related
- 2002-10-31 US US10/494,004 patent/US20050048027A1/en not_active Abandoned
- 2002-10-31 EA EA200801714A patent/EA013707B1/ru not_active IP Right Cessation
- 2002-10-31 SI SI200230980T patent/SI1997510T1/sl unknown
- 2002-10-31 ES ES02785348T patent/ES2311070T3/es not_active Expired - Lifetime
- 2002-10-31 HR HRP20040383AA patent/HRP20040383B1/xx not_active IP Right Cessation
- 2002-10-31 PT PT02785348T patent/PT1441757E/pt unknown
- 2002-10-31 EA EA201000386A patent/EA201000386A1/ru unknown
- 2002-10-31 DK DK08012976.0T patent/DK1997510T3/da active
- 2002-10-31 MX MXPA04004155A patent/MXPA04004155A/es active IP Right Grant
- 2002-10-31 WO PCT/EP2002/012204 patent/WO2003037363A2/fr not_active Ceased
- 2002-10-31 EP EP08012976A patent/EP1997510B1/fr not_active Expired - Lifetime
- 2002-10-31 EA EA200400624A patent/EA010858B1/ru not_active IP Right Cessation
- 2002-10-31 ES ES08012976T patent/ES2382224T3/es not_active Expired - Lifetime
- 2002-10-31 NZ NZ545414A patent/NZ545414A/en not_active IP Right Cessation
- 2002-10-31 KR KR1020097025518A patent/KR20090128583A/ko not_active Ceased
- 2002-10-31 KR KR1020047006691A patent/KR100816221B1/ko not_active Expired - Fee Related
- 2002-10-31 DE DE50212548T patent/DE50212548D1/de not_active Expired - Lifetime
- 2002-10-31 CA CA2465792A patent/CA2465792C/fr not_active Expired - Fee Related
- 2002-10-31 AU AU2002350660A patent/AU2002350660C1/en not_active Ceased
- 2002-10-31 EP EP02785348A patent/EP1441757B1/fr not_active Expired - Lifetime
- 2002-10-31 JP JP2003539706A patent/JP5004407B2/ja not_active Expired - Fee Related
- 2002-10-31 AT AT08012976T patent/ATE547115T1/de active
- 2002-10-31 KR KR1020077017712A patent/KR20070087248A/ko not_active Ceased
- 2002-10-31 PT PT08012976T patent/PT1997510E/pt unknown
- 2002-10-31 CN CNA2007101051509A patent/CN101156948A/zh active Pending
- 2002-10-31 EP EP10011603A patent/EP2368567A1/fr not_active Withdrawn
- 2002-10-31 SI SI200230745T patent/SI1441757T1/sl unknown
- 2002-10-31 SG SG200604427-5A patent/SG148034A1/en unknown
2004
- 2004-04-30 ZA ZA200403285A patent/ZA200403285B/en unknown
- 2004-06-01 NO NO20042262A patent/NO329789B1/no not_active IP Right Cessation
2005
- 2005-12-20 US US11/311,475 patent/US20060142195A1/en not_active Abandoned
2008
- 2008-06-27 US US12/163,828 patent/US8071091B2/en not_active Expired - Fee Related
- 2008-08-22 US US12/196,785 patent/US8119597B2/en not_active Expired - Fee Related
- 2008-10-23 CY CY20081101193T patent/CY1108446T1/el unknown
2009
- 2009-01-05 JP JP2009000322A patent/JP2009137983A/ja not_active Withdrawn
- 2009-11-19 CY CY20091101206T patent/CY1109648T1/el unknown
2010
- 2010-05-11 IL IL205695A patent/IL205695A0/en unknown
2012
- 2012-02-10 US US13/370,706 patent/US20130039902A1/en not_active Abandoned
- 2012-04-30 CY CY20121100407T patent/CY1112957T1/el unknown
2014
- 2014-01-09 US US14/151,390 patent/US20140199287A1/en not_active Abandoned
2016
- 2016-03-24 US US15/079,550 patent/US20170051268A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1441757A2 (fr)	2004-08-04
US20090004176A1 (en)	2009-01-01
KR20050042234A (ko)	2005-05-06
CA2465792C (fr)	2014-04-01
US20170051268A1 (en)	2017-02-23
HRP20040383A2 (en)	2005-08-31
DK1308166T3 (da)	2009-12-14
DK1997510T3 (da)	2012-05-21
HUP0402165A3 (en)	2010-01-28
HK1057328A1 (zh)	2004-04-02
ZA200403285B (en)	2005-07-27
NZ545414A (en)	2008-09-26
EP1997510A8 (fr)	2011-04-13
ES2382224T3 (es)	2012-06-06
EA200400624A1 (ru)	2004-10-28
CA2465792A1 (fr)	2003-05-08
DE50115077D1 (de)	2009-10-08
HU230163B1 (hu)	2015-09-28
NO329789B1 (no)	2010-12-20
KR20070087248A (ko)	2007-08-27
CN1592634A (zh)	2005-03-09
CY1108446T1 (el)	2014-04-09
EP1308166A1 (fr)	2003-05-07
CY1109648T1 (el)	2014-08-13
NO20042262L (no)	2004-06-01
BR0213856A (pt)	2004-08-31
JP2005519025A (ja)	2005-06-30
DE50212548D1 (de)	2008-09-04
JP5004407B2 (ja)	2012-08-22
EP1308166B1 (fr)	2009-08-26
AU2002350660C1 (en)	2008-10-09
DK1441757T3 (da)	2008-11-17
US20130039902A1 (en)	2013-02-14
NZ532903A (en)	2006-10-27
EA201000386A1 (ru)	2011-06-30
PL208343B1 (pl)	2011-04-29
WO2003037363A2 (fr)	2003-05-08
EA013707B1 (ru)	2010-06-30
PT1441757E (pt)	2008-11-03
PL369872A1 (en)	2005-05-02
EP1997510A1 (fr)	2008-12-03
EP1997510B1 (fr)	2012-02-29
KR100816221B1 (ko)	2008-03-24
EA200801714A1 (ru)	2008-12-30
EP1441757B1 (fr)	2008-07-23
HUP0402165A2 (hu)	2005-01-28
PT1308166E (pt)	2009-11-27
SI1441757T1 (sl)	2009-02-28
NO20042262D0 (no)	2004-06-01
US20090263373A1 (en)	2009-10-22
US20140199287A1 (en)	2014-07-17
ATE547115T1 (de)	2012-03-15
EA010858B1 (ru)	2008-12-30
CN100446810C (zh)	2008-12-31
ES2332576T3 (es)	2010-02-09
US20050048027A1 (en)	2005-03-03
JP2009137983A (ja)	2009-06-25
EP2368567A1 (fr)	2011-09-28
AU2002350660B2 (en)	2008-04-10
PT1997510E (pt)	2012-05-21
IL205695A0 (en)	2010-11-30
US8119597B2 (en)	2012-02-21
ES2311070T3 (es)	2009-02-01
CY1112957T1 (el)	2016-04-13
US8071091B2 (en)	2011-12-06
KR20090128583A (ko)	2009-12-15
WO2003037363A3 (fr)	2003-09-18
CN101156948A (zh)	2008-04-09
HRP20040383B1 (hr)	2012-08-31
ATE401910T1 (de)	2008-08-15
MXPA04004155A (es)	2005-03-31
ATE440614T1 (de)	2009-09-15
SI1997510T1 (sl)	2012-06-29
US20060142195A1 (en)	2006-06-29
DE10153601A1 (de)	2003-05-22

Publication	Publication Date	Title
CY1108446T1 (el)	2014-04-09	Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
MY136707A (en)	2008-11-28	Thrombopoietin mimetics
HRP20040042A2 (en)	2005-04-30	Substituted oxazolidinones for combinational therapy
DE60111570D1 (de)	2005-07-21	Isoindolin-1-on als glukokinaseaktivatoren
DK0703786T3 (da)	2002-05-27	Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
MY137828A (en)	2009-03-31	Keratinocytes which may be used as a biologically active substances for the treatment of wounds
MXPA04004306A (es)	2004-08-11	Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
HRP20050903B1 (hr)	2013-11-22	Intravenska injekcija ne-neurotoksiäśnih aktivatora plazminogena za tretman kapi
YU8804A (sh)	2006-08-17	Jedno-dozni azitromicin
IL158738A0 (en)	2004-05-12	Novel use of 2-phenyl-substituted imidazotriazinones
GB0020504D0 (en)	2000-10-11	Therapeutic method
IL158186A0 (en)	2004-03-28	Pharmaceutically active compounds and methods of use
PL367401A1 (en)	2005-02-21	Utilization of buprenorphine in urinary incontinence therapy
MY151447A (en)	2014-05-30	Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
MXPA03008406A (es)	2004-01-29	Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
PL375354A1 (en)	2005-11-28	Use of treosulfan and derivatives thereof for treating multiple sclerosis
AU2001276323A1 (en)	2002-02-13	Use of n-oleoylethanolamine for treating psoriasis
WO2001079430A3 (fr)	2002-02-21	Nouveau polypeptide, serine protease humaine 9, et polynucleotide codant pour ce polypeptide
WO2003059334A3 (fr)	2003-10-30	Gemcitabine pour traiter la variole
UA33498A (uk)	2001-02-15	Спосіб лікування терапевтично резистентних форм шизофренії
WO2001083676A3 (fr)	2002-02-28	Nouveau polypeptide, phosphatase humaine 10 fortement striee, et polynucleotide codant pour ce polypeptide
WO2001075030A3 (fr)	2002-01-03	Nouveau polypeptide, tyrosinase humaine 11, et polynucleotide codant pour ce polypeptide
GB0031196D0 (en)	2001-01-31	Recombinant human plasminogen and plasmin: methods for high yield production stabilization and use for treatment
WO2001079432A3 (fr)	2002-03-21	Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 58, et polynucleotide codant pour ce polypeptide
WO2001083758A3 (fr)	2002-04-25	Nouveau polypeptide, dihydroorotase humaine 8, et polynucleotide codant pour ce polypeptide